[go: up one dir, main page]

CL2017000885A1 - Anticuerpos anti-ox40 humanizados y usos de los mismos - Google Patents

Anticuerpos anti-ox40 humanizados y usos de los mismos

Info

Publication number
CL2017000885A1
CL2017000885A1 CL2017000885A CL2017000885A CL2017000885A1 CL 2017000885 A1 CL2017000885 A1 CL 2017000885A1 CL 2017000885 A CL2017000885 A CL 2017000885A CL 2017000885 A CL2017000885 A CL 2017000885A CL 2017000885 A1 CL2017000885 A1 CL 2017000885A1
Authority
CL
Chile
Prior art keywords
antibodies
humanized anti
methods
producing
cancer treatment
Prior art date
Application number
CL2017000885A
Other languages
English (en)
Inventor
Melissa Damschroder
Scott A Hammond
Michael Oberst
Qun Du
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of CL2017000885A1 publication Critical patent/CL2017000885A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>LA DESCRIPCIÓN PROPORCIONA ANTICUERPOS ANTI-OX40 HUMANIZADOS. TAMBIÉN SE PROPORCIONAN MÉTODOS DE PRODUCIR TALES ANTICUERPOS, Y MÉTODOS DE USO, P. EJ., TRATAMIENTO DEL CÁNCER.</p>
CL2017000885A 2014-10-10 2017-04-10 Anticuerpos anti-ox40 humanizados y usos de los mismos CL2017000885A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462062431P 2014-10-10 2014-10-10

Publications (1)

Publication Number Publication Date
CL2017000885A1 true CL2017000885A1 (es) 2017-12-15

Family

ID=55130798

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000885A CL2017000885A1 (es) 2014-10-10 2017-04-10 Anticuerpos anti-ox40 humanizados y usos de los mismos

Country Status (19)

Country Link
US (3) US9738723B2 (es)
EP (1) EP3204422B1 (es)
JP (2) JP6794348B2 (es)
KR (1) KR20170064550A (es)
CN (1) CN107074953A (es)
AR (1) AR102239A1 (es)
AU (1) AU2015328090A1 (es)
BR (1) BR112017007170A2 (es)
CA (1) CA2963798A1 (es)
CL (1) CL2017000885A1 (es)
CO (1) CO2017004516A2 (es)
ES (1) ES2914177T3 (es)
GB (1) GB2536324A (es)
IL (1) IL251537A0 (es)
MX (1) MX2017004715A (es)
RU (1) RU2709742C2 (es)
SG (1) SG11201702826XA (es)
TW (1) TW201619200A (es)
WO (1) WO2016057667A1 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014238546C1 (en) 2013-03-18 2019-01-17 Biocerox Products B.V. Humanized anti-CD134 (OX40) antibodies and uses thereof
EP3527587A1 (en) * 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
HRP20220811T1 (hr) * 2015-01-08 2022-09-30 BioNTech SE Agonistička sredstva za vezanje tnf receptora
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
SI3303396T1 (sl) 2015-05-29 2023-01-31 Bristol-Myers Squibb Company Protitelesa proti OX40 in njihova uporaba
MX2018003820A (es) 2015-10-02 2018-12-10 F Hoffmann ­La Roche Ag Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
CN114380908B (zh) 2015-10-15 2023-03-17 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
IL321475A (en) 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
AU2017298483A1 (en) * 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric OX40 binding molecules and uses thereof
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
BR122020025629B1 (pt) 2016-12-15 2022-05-31 Abbvie Biotherapeutics Inc Anticorpo anti-ox40, composição farmacêutica que compreende o mesmo e método in vitro para a produção do dito anticorpo
MX2019007144A (es) 2016-12-19 2019-10-07 Glenmark Pharmaceuticals Sa Nuevos agonistas de tnfr y sus usos.
EP3601345A1 (en) * 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
EP3612236A1 (en) 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy with an anti-cd25 antibody-drug conjugate
MX2019012464A (es) 2017-04-20 2019-12-11 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
JP2021501801A (ja) * 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
EP3713958A4 (en) * 2017-11-24 2021-11-03 Eucure (Beijing) Biopharma Co., Ltd ANTI-OX40 ANTIBODIES AND USES THEREOF
CN108218990B (zh) 2017-12-29 2021-03-02 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
CN111344019B (zh) 2017-12-29 2024-03-15 圆祥生技股份有限公司 调节免疫检查点作为癌症治疗的单特异性与双特异性蛋白质
CN110092832B (zh) * 2018-01-29 2020-03-31 康源博创生物科技(北京)有限公司 抗ox40抗体及其用途
WO2019178852A1 (zh) * 2018-03-23 2019-09-26 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
CN111918873B (zh) 2018-03-27 2025-06-24 百时美施贵宝公司 使用紫外线信号实时监测滴度
AU2019264712A1 (en) * 2018-05-11 2021-01-07 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against OX40, method for preparing same, and use thereof
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
BR112020023746A2 (pt) 2018-05-23 2021-02-17 Beigene, Ltd. anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico
CN112423845B (zh) 2018-07-12 2024-07-30 F-星治疗有限公司 结合pd-l1和cd137的抗体分子
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
ES3044118T3 (en) 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
CN111040034B (zh) * 2018-10-12 2022-08-30 广东旋玉健康生物科技有限公司 一种抗人cd358的单克隆抗体及其用途
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US12269890B2 (en) 2018-11-26 2025-04-08 Nanjing GenScript Biotech Co., Ltd. Humanized anti-human OX40 monoclonal antibody, preparation method therefor and use thereof
WO2020119789A1 (en) * 2018-12-14 2020-06-18 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
EP3904383A4 (en) * 2018-12-25 2022-08-17 Hanx Biopharmaceutics, Inc ANTI-OX40 MONOCLONAL ANTIBODY AND USE THEREOF
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
CA3131700A1 (en) 2019-02-27 2020-09-03 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
CA3134945A1 (en) * 2019-03-25 2020-10-01 Ohio State Innovation Foundation Combination immunoregulation and uses thereof
JP7645198B2 (ja) 2019-05-23 2025-03-13 ブリストル－マイヤーズ スクイブ カンパニー 細胞培養培地をモニターする方法
KR20220016156A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2021098757A1 (en) * 2019-11-21 2021-05-27 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
US20230011916A1 (en) * 2019-11-21 2023-01-12 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
MX2022006149A (es) * 2019-11-21 2022-06-17 Beigene Ltd Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tim3.
WO2021098749A1 (en) * 2019-11-21 2021-05-27 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in combination with radiation
KR20220103708A (ko) * 2019-11-21 2022-07-22 베이진 엘티디 항-pd1 또는 항-pdl1 항체와의 병용물 형태로 항-ox40 항체를 사용하는 암 치료의 방법
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
MX2022007712A (es) 2019-12-17 2022-09-26 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia.
JP7791402B2 (ja) 2020-03-23 2025-12-24 バイオ － テラ ソリューションズ、リミテッド 免疫細胞活性化剤の開発及び応用
CN115461366B (zh) 2020-04-17 2025-11-11 和记黄埔医药（上海）有限公司 抗ox40抗体及其用途
US20230183366A1 (en) * 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4225770A1 (en) 2020-10-05 2023-08-16 Bristol-Myers Squibb Company Methods for concentrating proteins
CN114457022A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
DK4267105T3 (da) 2020-12-28 2025-05-19 Bristol Myers Squibb Co Antistofsammensætninger og fremgangsmåder til anvendelse deraf
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
KR20240038722A (ko) * 2021-06-29 2024-03-25 하이파이바이오 (에이치케이) 리미티드 항-ox40 모노클로날 항체 및 그의 사용 방법
EP4448579A1 (en) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies and methods of use
CA3240585A1 (en) 2021-12-17 2023-06-22 Wenfeng Xu Anti-ox40 antibodies, multispecific antibodies and methods of use
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
EP4493575A1 (en) 2022-03-18 2025-01-22 Bristol-Myers Squibb Company Methods of isolating polypeptides
CN114591988B (zh) * 2022-03-30 2023-01-13 北京贝来生物科技有限公司 一种激活肿瘤免疫的基因修饰干细胞制备方法
IL317319A (en) 2022-06-02 2025-01-01 Bristol Myers Squibb Co Antibody compounds and methods of using them
CN114966061B (zh) * 2022-07-28 2022-10-21 中国食品药品检定研究院 一种抗ox40抗体的生物活性检测方法
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
WO2001021658A1 (en) * 1999-09-24 2001-03-29 Human Genome Sciences, Inc. 32 human secreted proteins
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
SI2650020T1 (sl) 2005-05-06 2017-03-31 Providence Health & Services - Oregon Technology Transfer Trimerični OX40 imunoglobulinski fuzijski protein in postopek za njegovo uporabo
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
SI2056874T1 (sl) * 2006-08-21 2012-12-31 F. Hoffmann-La Roche Ag Terapija tumorjev s protitelesom proti vegf
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
RU2009135824A (ru) * 2007-02-27 2011-04-10 Дженентек, Инк. (Us) Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний
EP2851374B1 (en) * 2007-12-14 2017-05-03 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
EP2242762B1 (en) 2008-01-18 2015-12-16 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
SG188129A1 (en) 2008-02-08 2013-03-28 Medimmune Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
JP5782385B2 (ja) * 2009-02-17 2015-09-24 ユーシービー ファーマ ソシエテ アノニム ヒトｏｘ４０に対する特異性を有する抗体分子
WO2013028231A1 (en) * 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
EA036047B1 (ru) * 2011-07-11 2020-09-18 Икнос Сайенсиз Са Антитела, которые связываются с ox40, и их применение
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US9828432B2 (en) 2012-02-06 2017-11-28 Providence Health & Services—Oregon Cancer treatment and monitoring methods using OX40 agonists
HK1205691A1 (en) * 2012-03-02 2015-12-24 Providence Health & Services - Oregon Dual ox40 agonist/il-2 cancer therapy methods
US9409977B2 (en) * 2013-03-12 2016-08-09 Decimmune Therapeutics, Inc. Humanized, anti-N2 antibodies
AU2014238546C1 (en) * 2013-03-18 2019-01-17 Biocerox Products B.V. Humanized anti-CD134 (OX40) antibodies and uses thereof

Also Published As

Publication number Publication date
RU2709742C2 (ru) 2019-12-19
US9738723B2 (en) 2017-08-22
AR102239A1 (es) 2017-02-15
TW201619200A (zh) 2016-06-01
JP2017532037A (ja) 2017-11-02
IL251537A0 (en) 2017-05-29
RU2017115662A (ru) 2018-11-13
US20180072808A1 (en) 2018-03-15
US20190169303A1 (en) 2019-06-06
AU2015328090A1 (en) 2017-04-27
JP2021036887A (ja) 2021-03-11
EP3204422A4 (en) 2018-08-15
EP3204422B1 (en) 2022-03-30
SG11201702826XA (en) 2017-05-30
US10150815B2 (en) 2018-12-11
KR20170064550A (ko) 2017-06-09
CO2017004516A2 (es) 2017-09-29
EP3204422A1 (en) 2017-08-16
JP6794348B2 (ja) 2020-12-09
CN107074953A (zh) 2017-08-18
CA2963798A1 (en) 2016-04-14
ES2914177T3 (es) 2022-06-07
MX2017004715A (es) 2017-06-19
WO2016057667A1 (en) 2016-04-14
US20160137740A1 (en) 2016-05-19
RU2017115662A3 (es) 2019-05-20
BR112017007170A2 (pt) 2017-12-19
GB2536324A (en) 2016-09-14
GB201517855D0 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
CL2017000885A1 (es) Anticuerpos anti-ox40 humanizados y usos de los mismos
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CL2018000458A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
MX391051B (es) Anticuerpos anti-cd47 y usos de los mismos.
ECSP17034845A (es) Conjugados de anticuerpo- farmaco
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
MX382129B (es) Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso.
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
MY192927A (en) Fused bicyclic compounds for the treatment of disease
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
EA202092450A2 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей